RESUMEN
Pentamidine isethionate (PTMD) is an antiprotozoal agent used in different parasitic diseases as Human African Trypanosomiasis or Pneumocystis pneumonia. Given its side effects, numerous analogs are still under development worldwide. PTMD has been recently described having a potential activity in myotonic dystrophy (type 1). Here we present an UPLC method coupled to fluo or PDA detection for PTMD and one analog determination in rat plasma or urine. The chromatographic separation was achieved on a Acquity UPLC® HSS T3 analytical column using a mobile phase combining formic acid 0.1% (v/v) and acetonitrile (ACN) at a constant flow rate of 0.4 mL/min. Preliminary, an innovative µSPE (solid phase extraction) procedure using Oasis® WCX sorbent was processed and gave satisfying and reproducible results in terms of extraction yields. Additionally, the methods were successfully validated using the accuracy profiles approach (ß=95% and acceptance limits=15%) over the ranges 2.88-287.52 ng/mL and from 143.76 ng/mL to 1.72 µg/mL in rat plasma and urine for PTMD and for EBAB, from 4.23 to 423.39 ng/mL and from 211.69 ng/mL to 2.54 µg/mL for plasma and urine, respectively. The validated protocols were applied to a pharmacokinetic (PK) study on rats and permitted to point out some relevant PK parameters on PTMD and its studied analog.
Asunto(s)
Antiprotozoarios/análisis , Cromatografía Líquida de Alta Presión/métodos , Pentamidina/análisis , Animales , Masculino , Pentamidina/sangre , Pentamidina/orina , Ratas , Ratas Wistar , Extracción en Fase SólidaRESUMEN
Despite progress in modern chemotherapy to combat tuberculosis, the causative pathogen Mycobacterium tuberculosis (M.tb.) is far from eradicated. Bacillary resistance to anti-mycobacterial agents, bacillary persistence and human immunodeficiency virus (HIV) co-infection hamper current drug treatment to completely cure the infection, generating a constant demand for novel drug candidates to tackle these problems. A small library of novel heterocyclic compounds was screened in a rapid luminometric in vitro assay against the laboratory M.tb. strain H37Rv. A group of amidines was found to have the highest potency and was further evaluated for acute toxicity against C3A hepatocytes. Next, the most promising compounds were evaluated for activity against a multi-drug resistant clinical isolate. The group of amidines was also tested for their ability to kill intracellular M.tb. residing in mouse J774A.1 macrophages. Finally, we report on a correlation between the structural differences of the compounds and their anti-mycobacterial activity.
Asunto(s)
Antituberculosos/química , Antituberculosos/farmacología , Mycobacterium tuberculosis/efectos de los fármacos , Piperazinas/química , Piperazinas/farmacología , Animales , Antituberculosos/síntesis química , Antituberculosos/toxicidad , Línea Celular , Diseño de Fármacos , Hepatocitos/efectos de los fármacos , Humanos , Macrófagos/microbiología , Ratones , Piperazinas/síntesis química , Piperazinas/toxicidad , Tuberculosis/tratamiento farmacológicoRESUMEN
Three novel LC-UV methods for the determination of pentamidine (PTMD) and two of its new analogs in rat plasma are described. The chromatographic conditions (wavelength, acetonitrile percentage in the mobile phase, internal standard) were optimized to have an efficient selectivity. A pre-step of extraction was simultaneously developed for each compound. For PTMD, a solid phase extraction (SPE) with Oasis(®) HLB cartridges was selected, while for the analogs we used protein precipitation with acetonitrile. SPE for PTMD gave excellent results in terms of extraction yield (99.7 ± 2.8) whereas the recoveries for the analogs were not so high but were reproducible as well (64.6 ± 2.6 and 36.8 ± 1.6 for analog 1 and 2, respectively). By means of a recent strategy based on accuracy profiles (ß-expectation tolerance interval), the methods were successfully validated. ß was fixed at 95% and the acceptability limits at ± 15% as recommended by the FDA. The method was successfully validated for PTMD (29.6-586.54 ng/mL), analog 1 (74.23-742.3 ng/mL) and analog 2 (178.12-890.6 ng/mL). The first concentration level tested was considered as the LLOQ (lower limit of quantification) for PTMD and analog 1 whereas for analog 2, the LLOQ was not the first level tested and was raised to 178.12 ng/mL.
Asunto(s)
Antiprotozoarios/sangre , Antiprotozoarios/química , Análisis Químico de la Sangre/métodos , Pentamidina/análogos & derivados , Pentamidina/sangre , Animales , Antiprotozoarios/aislamiento & purificación , Antiprotozoarios/farmacocinética , Análisis Químico de la Sangre/normas , Cromatografía Liquida , Pentamidina/aislamiento & purificación , Pentamidina/farmacocinética , Ratas , Estándares de Referencia , Factores de TiempoRESUMEN
The search for the inhibitors of adenoviruses has been performed among the substances of new class NCM (nitrogen containing macroheterocycles) and their analogues that have high potential of pharmacological properties. We have found a number of NCM and their derivatives that inhibit the reproduction of adenoviruses to various degrees. For the prediction of NCM structure with antiadenoviral activity we have performed the computer modeling using QSAR approach on the basis of simplex representation of molecular structure (SiRMS).
Asunto(s)
Adenovirus Humanos/efectos de los fármacos , Antivirales , Compuestos Heterocíclicos , Nitrógeno/química , Antivirales/efectos adversos , Antivirales/química , Antivirales/farmacología , Compuestos Aza/efectos adversos , Compuestos Aza/química , Compuestos Aza/farmacología , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Efecto Citopatogénico Viral/efectos de los fármacos , Diseño de Fármacos , Compuestos Heterocíclicos/efectos adversos , Compuestos Heterocíclicos/química , Compuestos Heterocíclicos/farmacología , Humanos , Estructura Molecular , Piridinas/efectos adversos , Piridinas/química , Piridinas/farmacología , Relación Estructura-Actividad Cuantitativa , Replicación Viral/efectos de los fármacosRESUMEN
A series of quaternary ammonium salts has been tested as phase transfer agents to promote condensation reactions in an aqueous solution of sodium hydroxide in the absence of any organic solvent. Methyltrioctylammonium chloride (Aliquat 336) emerges as the most efficient catalyst. Sonication of the reaction media has a poor but positive kinetic effect.